Pharmaceuticals

Innovent Releases Final Analysis Results of ORIENT-15: the Phase 3 Study of Sintilimab plus Chemotherapy for the First-Line Treatment of Esophageal Squamous Cell Carcinoma at the AACR Annual Meeting 2023

ROCKVILLE, Md. and SUZHOU, China, April 17, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology a...

2023-04-17 08:33 3404

Abbisko presents the research results of 5 programs at the 2023 AACR Annual Meeting

SHANGHAI, April 17, 2023 /PRNewswire/ -- Abbisko (Stock Code: 2256.HK) announced the results of five latest preclinical studies at the 2023 American Association for Cancer Research (AACR) annual meeting. Abbisko These include its self-develo...

2023-04-17 08:30 3334

Innovent Releases Final Analysis Results of ORIENT-15: the Phase 3 Study of Sintilimab plus Chemotherapy for the First-Line Treatment of Esophageal Squamous Cell Carcinoma at the AACR Annual Meeting 2023

ROCKVILLE, Md. and SUZHOU, China, April 16, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology a...

2023-04-17 08:20 3128

Henlius Achieved Steep Revenue Growth in Q1 2023, Core Products Sales Surged

SHANGHAI, April 17, 2023 /PRNewswire/ -- As a global innovative biopharmaceutical company, Henlius is committed to offering high-quality, affordable and innovative biopharmaceuticals to patients worldwide with 5 products launched inChina. Leveraging the differentiated competitive edges of its pr...

2023-04-17 07:45 2387

Bugworks Research Inc. to Present Eight Posters at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) 2023, in Copenhagen, Denmark

BANGALORE, India and DELAWARE CITY, Del. and ADELAIDE, Australia, April 17, 2023 /PRNewswire/ -- Bugworks Research Inc., a clinical-stage biopharmaceutical company, is set to present its latest research findings on the novel bacterial topoisomerase inhibitor, BWC0977 at the upcoming 33rd European...

2023-04-17 07:00 2486

Olaratumab Antibody Licensed from Lilly Demonstrates Proof of Concept as a Theranostic Radiopharmaceutical

MELBOURNE, Australia, April 17, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces successful preclinical development of radiolabelled olaratumab, an antibody licensed from Eli Lilly and Company (Lilly). Telix has demonstrated proof-of-concept (PoC) ...

2023-04-17 06:38 1959

Minghui Pharmaceutical Inc. Announces Phase 2 Clinical Trial Success of MH004 Cream as a Potential Best-in-Class Topical Treatment for Mild-to-Moderate Atopic Dermatitis and the FDA Clearance of its Global Phase 3 MRCT

* Study met both primary and all key secondary endpoints * Mean percentage change from baseline in Eczema Area and Severity Index (EASI) score was -78.7% in 1.0% MH004 Cream-treated group compared to -46.7% in vehicle group * 79.6% individuals treated with 1.0% MH004 Cream achieved EASI-75 c...

2023-04-14 19:00 6534

CytoMed Therapeutics Limited Announces Pricing of Initial Public Offering

SINGAPORE, April 14, 2023 /PRNewswire/ -- CytoMed Therapeutics Limited ("CytoMed" or the "Company"), a pre-clinical biopharmaceutical company focused on harnessing its licensed proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers, today announced ...

2023-04-14 08:00 4343

Zenshine Pharmaceuticals' ZX-7101A Met the Primary Endpoint of the Phase 2 Study for the Treatment of Acute Uncomplicated Influenza in Adults

NANJING, China, April 13, 2023 /PRNewswire/ -- On April 1st, 2023, during the First Infection Collaboration Forum of the Chinese National Center for Infectious Diseases, Nanjing Zenshine Pharmaceuticals Co., Ltd. (Zenshine Pharmaceuticals) announced that its proprietary anti-influenza agent ZX-71...

2023-04-14 01:15 2005

The Dates of the XXVII Edition of the International Fair Play Menarini Awards

FLORENCE, Italy, April 13, 2023 /PRNewswire/ -- Preparations are already underway for theInternational Fair Play Menarini Awards. This year,  the event that pays tribute to athletes who demonstrate values such as ethics, loyalty and respect both in sport and in life, is in itsXXVII edition and wi...

2023-04-13 18:50 2510

Caring Pharmacy partners with Appier to deliver a personalized multi-channel experience for Malaysians

TAIPEI, April 13, 2023 /PRNewswire/ -- Appier  (TSE: 4180) today announced the successful campaign results from its partnership with Caring Pharmacy, a leading pharmacy chain inMalaysia, to enhance its overall multi-channel marketing strategy. Caring Pharmacy enabled highl...

2023-04-13 14:00 2682

EW GROUP SHINES AT 12TH A4M SYMPOSIUM 2023 & "ALL-ON BIOREGEN OPTIMIZATION" WORKSHOP

BANGKOK, April 13, 2023 /PRNewswire/ -- European Wellness Biomedical Group (EW Group) made a successful showing at an exclusive event, the 12th A4M Symposium 2023, which was held in Centara,Bangkok, 16th-19th February 2023. The two-day A4M Symposium, commenced with a welcome ceremony featuring ...

2023-04-13 12:20 2774

Viva Biotech Attended SAPA-China

HONG KONG, April 12, 2023 /PRNewswire/ -- 6th-7th April, the "2022 SAPA-China Annual Conference - Opportunities and Challenges for the Development ofChina's Biopharmaceutical Industry" hosted by The Sino-American Pharmaceutical Professionals Association (SAPA) was held inChengdu, Sichuan. Viva Bi...

2023-04-13 11:33 2287

Altair to Showcase Pharmaceutical Process Optimization Technology at the Korea Pharm&Bio 2023

Altair will feature pharmaceutical manufacturing process simulation and data analytics technologies SEONGNAM, South Korea, April 13, 2023 /PRNewswire/ -- Altair (Nasdaq: ALTR), a global leader in computational science and artificial intelligence (AI), will be exhibiting at Korea Pharm&Bio,April ...

2023-04-13 08:00 3247

Bridge Biotherapeutics Announces First Patient Dosed in its Phase 2a Clinical Trial of BBT-877, a Potent Autotaxin Inhibitor for the Treatment of Idiopathic Pulmonary Fibrosis

SEONGNAM, South Korea and CAMBRIDGE, Mass., April 12, 2023 /PRNewswire/ -- Bridge Biotherapeutics (KQ288330), a clinical-stage biotech company based in South Korea developing novel drugs for fibrosis, cancer, and inflammation, announced it has dosed the first patient in its Phase 2a clinical study...

2023-04-13 06:00 1876

Standigm announces Younsung Choo as chief executive officer

Former LG life Sciences exec and long-time Standigm advisor brings extensive experience in pharmaceuticals and project management SEOUL, South Korea, April 12, 2023 /PRNewswire/ -- Standigm , a company using artificial intelligence (AI) technology for drug discover...

2023-04-13 00:07 2077

GC Genome-KAIST team Announces Publication of a Groundbreaking AI-Based Liquid Biopsy Technology for Multi-Cancer Early Detection and Localization in Nature Communications

YONGIN, South Korea, April 11, 2023 /PRNewswire/ -- GC Genome Corporation, a leading genomic diagnostics company, today announced the publication of a new study inNature Communications, showcasing the company's novel AI-based liquid biopsy technology. The study highlights the unprecedented accura...

2023-04-12 11:06 1749

Specialised Therapeutics signs partnership agreement with Akeso Inc. and CTTQ-Akeso to commercialise new anti-PD1 antibody in Australia and Southeast Asia

SINGAPORE, April 11, 2023 /PRNewswire/ -- Independent biopharmaceutical company Specialised Therapeutics Asia Pte Ltd (ST) will partner with CTTQ-Akeso ( Shanghai) Biomed. Tech. Co., Ltd. (CTTQ-Akeso)(jointly established by Akeso, Inc. (9926.HK, Akeso) and Chia Tai Tianqing Pharmaceutical Group Co...

2023-04-12 06:00 2257

Boan Biotech's Biologics License Application for Boyounuo® (Bevacizumab Injection) Accepted in Brazil

YANTAI, China, April 11, 2023 /PRNewswire/ -- Boan Biotech today announced that Brazil's Agência Nacional de Vigilância Sanitária (ANVISA) has accepted the company's Biologics License Application (BLA) for Boyounuo® (Bevacizumab Injection). Envisioned to be "a leading global biopharmaceutical co...

2023-04-11 20:19 3686

OnCusp Therapeutics Showcases Potent Anti-Tumor Activity of its CDH6 ADC at AACR Annual Meeting 2023

NEW YORK, April 11, 2023 /PRNewswire/ -- OnCusp Therapeutics, a global biopharmaceutical company dedicated to transforming cutting-edge preclinical innovation into clinically validated treatments for cancer patients worldwide, today announced that the preclinical data on its lead program CUSP0...

2023-04-11 20:00 1475
1 ... 113114115116117118119 ... 315